KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Research & Development (2016 - 2025)

Historic Research & Development for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $98.3 million.

  • Novavax's Research & Development rose 1274.61% to $98.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.8 million, marking a year-over-year decrease of 1786.59%. This contributed to the annual value of $391.2 million for FY2024, which is 4696.03% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Research & Development is $98.3 million, which was up 1274.61% from $79.2 million recorded in Q2 2025.
  • Novavax's Research & Development's 5-year high stood at $963.0 million during Q4 2021, with a 5-year trough of $79.2 million in Q2 2025.
  • Moreover, its 5-year median value for Research & Development was $219.5 million (2023), whereas its average is $271.8 million.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 340796.69% in 2021, then crashed by 7322.31% in 2022.
  • Novavax's Research & Development (Quarter) stood at $963.0 million in 2021, then plummeted by 73.22% to $257.8 million in 2022, then tumbled by 36.13% to $164.7 million in 2023, then crashed by 36.62% to $104.4 million in 2024, then fell by 5.85% to $98.3 million in 2025.
  • Its Research & Development stands at $98.3 million for Q3 2025, versus $79.2 million for Q2 2025 and $88.9 million for Q1 2025.